Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

February 04, 2010 08:00 ET

Afexa Life Sciences Inc., Maker of COLD-FX®, Appoints Michael D. Obert as Chief Legal Officer and Senior Vice President Corporate Development

EDMONTON, ALBERTA--(Marketwire - Feb. 4, 2010) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA), maker of COLD-FX, announced that Michael D. Obert has joined the Company as Chief Legal Officer and Senior Vice President Corporate Development. He will serve on Afexa's Executive Leadership Team, and will report directly to the Chairman and Chief Executive Officer.

"Afexa has an ambitious plan for growth and we are looking forward to Michael's contribution to our strategic decision-making and implementation as well as to the day-to-day operations of the business," said Afexa's Chairman and CEO, Jack Moffatt. "Mr. Obert's extensive legal experience as well as his general business experience gained from working with many private and public companies will be very valuable in helping us meet Afexa's business objectives." Mr. Obert's mandate will also include an important role as advisor to the Board of Directors, further strengthening the Board's oversight role, and providing guidance, direction and advice on legal and ethical decision-making in line with the Company's mission, vision and values.

Before joining Afexa, Mr. Obert was a partner with Fraser Milner Casgrain LLP where he has spent the last 30 years as a respected corporate-commercial lawyer specializing in the technology/biotechnology field. Among other areas, he has wide-ranging experience in mergers and acquisitions, joint ventures, private and public financings, licensing, corporate governance, securities and technology law, and in dealing with stock exchanges, securities commissions and other regulators.


Afexa Life Sciences Inc., founded in 1992, strives to deliver the most trusted health brand on the planet through pioneering evidence-based natural medicines that empower people to achieve their health potential. The Company's patented ChemBioPrint® discovery and standardization technology enables the development of effective and safe medicines from complex natural sources, while ensuring reliable health benefits and batch-to-batch consistency. COLD-FX®, a ChemBioPrint product, is the Company's flagship product and Canada's leading over-the-counter (OTC) cold and flu remedy. It is officially indicated in Canada to help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system. COLD-FX has a product license (NPN) and is supported by scientific evidence, including randomized, double-blind, placebo-controlled clinical trials.

This news release contains certain forward-looking statements and information within the meaning of applicable securities laws, which reflect current expectations of the management of Afexa Life Sciences Inc. (the "Company") regarding future events or the Company's future performance. All statements other than statements of historical fact contained in this news release may be forward-looking statements. The forward-looking information included in this document does not guarantee future performance and should not be unduly relied upon. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including, without limitation comments that could be impacted by competition, the incidence of cold and flu, consumer confidence and spending levels, general economic conditions, interest and currency exchange rates, unseasonable weather patterns, the cost and availability of capital and grants/funding, product development uncertainties, labour market challenges, consumer acceptance of Afexa's products in other markets. The Company believes that the expectations and assumptions reflected in the forward-looking information contained herein are reasonable but no assurance can be given that these expectations and assumptions are correct or that that the results, performance or achievements expressed in, or implied by, forward-looking statements herein will occur, or if they do, that any benefits may be derived from them. The Company can give no assurance that new product development initiatives will lead to new product commercialization or that significant hires will assist the Company in meeting its business plan or that the business plan will result in growth for the Company. The Company assumes no duty to update or revise forward looking information, except as may be required pursuant to applicable laws. All forward-looking information is expressly qualified in its entirety by this cautionary statement. Further information regarding risks and uncertainties relating to the Company and its securities can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at The Company claims exemption under U.S. SEC Rule 12g3-2(b).

Contact Information